Preferred Label : cancer, second primary;

UMLS semantic type : T191 - Neoplastic Process;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://ansm.sante.fr/informations-de-securite/xgeva-denosumab-v-risque-de-second-cancer-primitif
2018
false
false
false
France
French
pharmacovigilance note
Denosumab
denosumab
injections, subcutaneous
neoplasms, second primary
Advanced Malignant Neoplasm
risk assessment
bone neoplasms
giant cell tumor of bone
product surveillance, postmarketing
cancer, second primary

---
https://www.e-cancer.fr/Professionnels-de-sante/Facteurs-de-risque-et-de-protection/Second-cancer-primitif
2013
France
scientific and technical information
risk factor for malignancy
risk factors
cancer, second primary
Second cancer
Protective Factors
neoplasms, second primary
neoplasm, malignant
risk factor

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.